source
- Argenx acquires Unnatural Products for up to $1.15 billion to boost oral peptide platformArgenx announced it will buy biotech Unnatural Products, paying $550 million upfront with the total deal value potentially reaching $1.15 billion through development and regulatory milestones. The…
- Vir Biotechnology's Phase 3 Trial Shows Primary Endpoint Success in Chronic Hepatitis DeltaVir Biotechnology reported that its phase 3 Eclipse 1 trial in chronic hepatitis delta met the primary endpoint. At week 48, 44% of patients who began treatment immediately showed undetectable HDV…